Quantcast

West Coast Cancer Center Breaks Ground on New Building to House CyberKnife System

August 28, 2008

SUNNYVALE, Calif., Aug. 28 /PRNewswire-FirstCall/ — Accuray Incorporated , a global leader in the field of radiosurgery, announced today that the Comprehensive Blood and Cancer Center (CBCC) — one of the nation’s largest freestanding, physician owned and operated comprehensive cancer centers — has purchased a CyberKnife(R) Robotic Radiosurgery System for its seven-acre campus in Bakersfield, Calif.

The CyberKnife System is the newest addition to a broad spectrum of technologies and treatments that CBCC offers cancer patients. The CyberKnife System will allow physicians to deliver targeted radiosurgery to a tumor located anywhere in the body from virtually unlimited positions. The CyberKnife System enables the physician to achieve unprecedented accuracy with sub-millimeter precision thus minimizing damage to surrounding healthy tissue.

“We have a philosophy and commitment to bringing the most promising treatments and the most sophisticated technology to our community as quickly as possible. The new CyberKnife System will allow us to treat patients who were untreatable in the past,” said Dr. Ravi Patel, founder and chairman of CBCC. “This technology will make a significant difference in the quality of life for our patients and will give CBCC the capability to treat tumors that have previously been inoperable.”

“With CBCC’s purchase of CyberKnife System, we are increasing the access cancer patients have to cutting-edge treatment technology,” said Eric P. Lindquist, senior vice president and chief marketing officer at Accuray. “Accuray is proud to assist CBCC in their quest to provide patients with the most advanced cancer care available today.”

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 50,000 patients worldwide and currently more than 140 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com/.

About CBCC, USA

Comprehensive Blood & Cancer Center (CBCC) was founded by Dr. Ravi Patel in 1984 with the sole mission of providing compassionate care for diagnosis, treatment, patient education and prevention of cancer using a state-of-the-art treatment approach. CBCC’s facilities, located in Bakersfield, Calif., occupy more than 75,000 sq. feet on a seven acre site. CBCC has been a leader in oncology in the areas of patient care, technology and clinical research. CBCC facilities treat more than 5,000 new patients per year and have more than 150,000 patient visits annually. Additional information is available on CBCC’s website at http://www.cbccusa.com/.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the year ended June 3, 2007 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission including our report on Form 10-K for fiscal 2008 when filed. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Accuray Incorporated

CONTACT: Stephanie Tomei, Public Relations Manager of AccurayIncorporated, +1-408-789-4234, stomei@accuray.com; Susan Lehman,+1-510-832-6006, susan@rockpointpr.com, of Rockpoint Public Relations forAccuray Incorporated

Web site: http://www.accuray.com/




comments powered by Disqus